Hence, we retrospectively analyzed the clinical data, biomarkers in CSF, and pathology of patients with astrocyte antibodies to confirm the presence of autoimmune astrocytopathy beyond AQP4 and GFAP autoimmunity and provide new insights into diagnosis and therapy. This evidence concerns the gene GFAP and Autoimmunity.